Lincoln Pharmaceuticals Declares 18% Final Dividend; Record Date Set for September 12

Ahmedabad, August 29, 2025 – Lincoln Pharmaceuticals Limited (NSE: LINCOLN, BSE: 531633) has announced a final dividend of ₹1.80 per share on the face value of ₹10 (18% dividend). The company also announced that its 31st Annual General Meeting (AGM) will be held on Tuesday, September 30, 2025, at 11:00 a.m. (IST) through video conferencing. The dividend is subject to shareholders’ approval at the AGM, and the record date will be Friday, September 12, 2025.

Lincoln Pharmaceuticals Limited, founded in 1979 and headquartered in Ahmedabad, is a publicly listed pharmaceutical company with WHO-GMP, EU-GMP, and TGA-approved manufacturing facilities in Gujarat. It offers a wide portfolio of over 1,700 formulations, including tablets, injectables, and topical products, supported by a strong R&D team and over 50 new launches annually. With a workforce of ~1,600, the company exports to nearly 60 countries across Europe, the Americas, Africa, and Asia.

Stock Market Snapshot

At 01:45 PM, the stock traded at ₹540 per share (0.59% lower from the previous day’s closing price). The stock has plummeted by almost 24% in the past year. The low-high range so far has been ₹539-₹547. The P/E Ratio is 12.60 compared to the Industrial Average of 34.66.

Dividend Details and History

The company has a history of paying consistent dividends in the past five years. In the current and immediately preceding year, the dividend rate was 18%, and before that, it was 15% for three years. The book closure period will be from September 13 to September 30.

REF: https://nsearchives.nseindia.com/corporate/LINCOLN_29082025113842_Intimation_-Intimation_of_Record_Date.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations